We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Cancer drug sponsors should consider informing the public about pricing and reimbursement decisions, including the rationale behind them, as well as reporting R&D and any public funding sources, WHO suggests. Read More
“It is vital that Government makes minimizing disruption to the medicines supply the highest priority as it prepares for a potential hard or disorderly… Read More
Insurers and hospitals will be allowed to pay drugmakers based on the effectiveness of their products, if a bipartisan Senate bill that amends the Social Security Act is passed. Read More
The European Medicines Agency began a six-month public consultation Thursday for draft principles on a common EU standard for human drug electronic product information. Read More
HHS released a proposed rule on Thursday that would target “backdoor” rebates between drugmakers and pharmacy benefit managers (PBMs), restructuring the rebate system to pass the discounts directly on to consumers. Read More
The contingency legislation is needed in order for the Medicines and Healthcare products Regulatory Agency to take on regulatory processes that are currently undertaken by the European Medicines Agency and other bodies. Read More
Scilex Pharmaceuticals urged the FDA to remove unapproved lidocaine patches from the market and issue guidance on the marketing of such products. Read More